Vita Life Sciences (ASX:VLS) Cash-to-Debt : 55.32 (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Vita Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vita Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2024 was 55.32.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vita Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Vita Life Sciences's Cash-to-Debt or its related term are showing as below:

ASX:VLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.46 Med: 6.13 Max: 113.26
Current: 55.32

During the past 13 years, Vita Life Sciences's highest Cash to Debt Ratio was 113.26. The lowest was 3.46. And the median was 6.13.

ASX:VLS's Cash-to-Debt is ranked better than
85.45% of 1010 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs ASX:VLS: 55.32

Vita Life Sciences Cash-to-Debt Historical Data

The historical data trend for Vita Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vita Life Sciences Cash-to-Debt Chart

Vita Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

6.99

42.61

26.10

113.26

55.32

Vita Life Sciences Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															26.10	40.32	113.26	64.53	55.32

Competitive Comparison of Vita Life Sciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vita Life Sciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vita Life Sciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Vita Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vita Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.601	/	(0.303	+	0.214)
	=	55.32

Vita Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.601	/	(0.303	+	0.214)
	=	55.32

Vita Life Sciences (ASX:VLS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vita Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vita Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vita Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vita Life Sciences Ltd (ASX:VLS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bath Road Kirrawee, Unit 1/ 102, Sydney, NSW, AUS, 2232

Website

https://www.vitalifesciences.com

Vita Life Sciences Ltd is an Australian based pharmaceutical and healthcare company involved in formulating, packaging, sales, and distribution of vitamins and supplements. The company produces a wide range of premium supplements, vitamins, minerals, herbs and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold brands throughout Asia-Pacific region. The company has four reportable segments which include The Australia segment comprises of sale of Herbs of Gold range in Australia and exports into China. The Singapore and Malaysia segment, comprise of Vitahealth and Herbs of Gold range in both countries The other market segment comprises of Vitahealth ranges.

Vita Life Sciences Headlines

No Headlines